Authors
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal MalignanciesCirculating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.
Latest:
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewThis review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment LandscapeMedical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.
Latest:
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited InstitutionsSurgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple MyelomaA Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
Latest:
Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast CancerThe panelists conclude their discussion on HER2-positive breast cancer by underscoring the importance of preventive measures for brain metastases, enhanced strategies for managing leptomeningeal disease, and improved approaches to handle treatment-related toxicity.
Latest:
Characterization of Blood-Based Molecular Profiling in Pancreatic AdenocarcinomaMolecular profiling is being explored in pancreatic adenocarcinoma as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials.
Latest:
Spreading Greater CAR T-Cell Therapy Education in the Community SettingGreater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Latest:
Empowering Ovarian Cancer Patients: How to Educate and Support Those Starting ADC TherapyCounseling Patients on ADC Side Effects Patient education is a cornerstone of successful ADC treatment. When introducing ADCs, providers focus on transparency—discussing the most common side effects upfront and reinforcing that many are reversible with dose holds or modifications. Eye toxicities and lung-related side effects like pneumonitis often cause anxiety. Clear communication and reassurance that these can be managed effectively help build trust. Educational materials and follow-up calls ensure patients feel supported and informed. Ultimately, the goal is to empower patients to report symptoms early and remain engaged in their care. ADC therapy offers significant clinical benefit, and with proactive management, patients can achieve extended survival and maintain their quality of life throughout treatment.
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
